Among different lymphoma models, nutlin has been shown effective in inducing wild type p53-dependent apoptosis of Hodgkin’s lymphoma (HL) [
67,
68], mantle cell lymphoma (MCL) [
69‐
72], ALK-positive anaplastic large cell lymphoma (ALCL) [
73], B-cell lymphoma (BCL) [
74,
75], Burkitt’s and follicular lymphoma [
76‐
78], and adult T cell leukemia [
79]. Interestingly, when combined with geldanamycin (an HSP90 inhibitor) nutlin exerted its apoptotic activity in both p53 wild type and mutant HL cells since geldanamycin-induced apoptosis in HL cells was p53-independent [
68]. MDM2 inhibition by nutlin successfully induced intrinsic mitochondrial apoptotic activation through increased expression of Noxa in refractory MCL cells, which had limited sensitivity to bortezomib alone. The Nutlin/bortezomib combination enhanced Noxa protein expression in mutant p53 cells but not in wild type p53 MCL cells [
71]. Similar to our observations in MM [
65], nutlin-induced apoptosis in ALCL cells involved both p53-mediated transcriptional and non-transcriptional mechanisms [
71,
73]. Recently, by both
in vitro and
in vivo evidence Drakos et al. demonstrated that nutlin induced cell cycle arrest and apoptosis in DLBCL cells with functional p53, t(14;18)(q32;q21) translocation, and Bcl2 over-expression [
75]. Importantly, combined treatment with nutlin and doxorubicin synergistically inhibited the growth of ALCL or DLBCL cells harboring either wild type or mutant p53 [
73,
75]. These studies also demonstrated that nutlin induced increased expression of p73 in MCL, ALCL, or BCL cells harboring mutant p53 [
72,
73,
75]
. Activation of p53 by nutlin resulted in both cellular senescence and apoptosis in ATL-related cell lines harboring wild type p53 suggesting that cellular senescence might be an important event in p53-dependent cell death in ATL cells [
79].